Retrophin Inc (RTRX) SVP Elizabeth E. Reed Sells 942 Shares
Retrophin Inc (NASDAQ:RTRX) SVP Elizabeth E. Reed sold 942 shares of the company’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $24.04, for a total transaction of $22,645.68. Following the sale, the senior vice president now directly owns 9,058 shares of the company’s stock, valued at approximately $217,754.32. The sale was disclosed in a filing with the SEC, which is available at this link.
Shares of Retrophin Inc (RTRX) opened at $23.58 on Tuesday. Retrophin Inc has a one year low of $15.55 and a one year high of $26.44. The company has a quick ratio of 3.83, a current ratio of 3.88 and a debt-to-equity ratio of 0.15. The firm has a market cap of $905.13, a P/E ratio of -17.86 and a beta of 1.45.
Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.21). Retrophin had a negative net margin of 33.79% and a negative return on equity of 10.13%. The firm had revenue of $40.34 million during the quarter, compared to analysts’ expectations of $40.51 million. During the same period last year, the company earned ($0.09) EPS. The business’s quarterly revenue was up 18.8% on a year-over-year basis. sell-side analysts forecast that Retrophin Inc will post -1.25 earnings per share for the current year.
Institutional investors have recently bought and sold shares of the company. Trexquant Investment LP purchased a new stake in shares of Retrophin in the 3rd quarter valued at approximately $203,000. SG Americas Securities LLC grew its stake in shares of Retrophin by 1.8% in the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 146 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Retrophin in the 3rd quarter valued at approximately $212,000. Legal & General Group Plc grew its stake in shares of Retrophin by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 355 shares during the period. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of Retrophin in the 3rd quarter worth approximately $249,000.
Several analysts have recently weighed in on RTRX shares. BidaskClub cut shares of Retrophin from a “buy” rating to a “hold” rating in a research note on Saturday, December 30th. ValuEngine cut shares of Retrophin from a “hold” rating to a “sell” rating in a research note on Monday, November 20th. Zacks Investment Research raised shares of Retrophin from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 4th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $44.00 price target on shares of Retrophin in a research note on Friday, October 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $44.00.
WARNING: “Retrophin Inc (RTRX) SVP Elizabeth E. Reed Sells 942 Shares” was originally published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/retrophin-inc-rtrx-svp-elizabeth-e-reed-sells-942-shares/1799409.html.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with Analyst Ratings Network's FREE daily email newsletter.